IntegraGen presented data at the 60th Annual meeting of the American Academy of Child & Adolescent Psychiatry in Orlando, Florida reporting on the identification of over 1,500 genetic variants associated with autism.
IntegraGen released financial results for the half year ending on June 30, 2013. Revenue grew by 18% compared to the first half of 2012.
IntegraGen's mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests for autism and oncology based on these discoveries. The company also strives to be a leader in providing cutting edge genomic services to academic researchers and life sciences companies based on it's technological expertise and scientific know how.